Ultrasound cancer treatment, supported by Li Ka-shing, gains traction in Asia: US expert
Focused ultrasound, backed by Li Ka-shing, is emerging as a non-invasive, commercially viable cancer treatment, attracting significant investments
Focused ultrasound, a non-invasive medical treatment supported by Hong Kong tycoon Li Ka-shing, is being recognised as a commercially attractive alternative to traditional therapies for many diseases including cancer, according to an expert.
“The growth in the number of treatments, clinical trials and research sites, and the fact that equipment manufacturers are getting investments from strategic investors and major financial institutions, are indications that focused ultrasound is scaling up,” the former co-chair of neurosurgery at the University of Virginia said.
The Hong Kong billionaire’s charity last month announced that it would donate two such machines to the city’s hospitals, sponsor the treatment of 20 patients and support the training of six doctors and radiologists by HistoSonics.
“It’s one of several devices that can treat liver cancer, but it uses a technology that breaks up and dissolves the tumour cells,” Kassell said. “This contrasts with thermal ablation, which destroys the tissues by heating them.”